Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety comparison of insulin detemir plus insulin aspart versus insulin glargine plus insulin aspart in type 1 diabetes.

Trial Profile

Efficacy and safety comparison of insulin detemir plus insulin aspart versus insulin glargine plus insulin aspart in type 1 diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Insulin detemir (Primary) ; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms NOVEL-1
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 May 2011 Last checked against European Clinical Trials Database record.
    • 07 Jul 2009 Actual end date (Dec 2004) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top